pioglitazone has been researched along with Atrial Septal Defect in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, D | 1 |
| Maisnam, I | 1 |
| Ghosh, S | 1 |
| Mukhopadhyay, S | 1 |
| Chowdhury, S | 1 |
1 other study available for pioglitazone and Atrial Septal Defect
| Article | Year |
|---|---|
Syndrome of extreme insulin resistance (Rabson-Mendenhall phenotype) with atrial septal defect: clinical presentation and treatment outcomes.
Topics: Adolescent; Donohue Syndrome; Female; Heart Septal Defects, Atrial; Humans; Hypoglycemic Agents; Ins | 2013 |